Estrogen therapy
“Ghrelin and Leptin Changes in Serum of Postmenopausal Osteoporotic Iraqi Women after Three Months Oral Estrogen Therapy” by Elaf Mahmood Shihab, Mustafa G. Alabbassi, Khudair Z. AL-Bedri, Inas Taha Ahmad, Iraq.
... of estrogen reduces the somatostatin inhibitory drive on growth hormone secretion, as reported by relevant pilot studies, in accordance with finding that central effect of ghrelin is at least partially mediated ...
5
Barriers to effective treatment of vaginal atrophy with local estrogen therapy
... local estrogen therapy to prime the vaginal epithelium and produce noticeable results (eg, relief of vaginal dryness, irritation, itching, and pain on ...local estrogen therapy should be ...
6
Soy isoflavones, estrogen therapy, and breast cancer risk: analysis and commentary
... to estrogen receptors and exhibit weak estrogen-like effects under certain experimental ...existing estrogen-sensitive breast ...the estrogen-like effects of isoflavones in the breast focusing ...
11
Overcoming resistance and barriers to the use of local estrogen therapy for the treatment of vaginal atrophy
... Local estrogen therapy is effective and safe for treatment of vaginal atrophy; however, barriers to treatment (eg, patient reluctance to discuss the condition, misinformation, incomplete understanding of ...
7
Postmenopausal vaginal atrophy: evaluation of treatment with local estrogen therapy
... To be eligible for study participation, women were required to be US residents $18 years of age, menopausal (ie, not presenting with a spontaneous menstrual period for $1 year, or having had a double oophorectomy) and in ...
8
Fibrinogen storage disease without hypofibrinogenemia associated with estrogen therapy
... thrombin time were also within normal limits. The patient had no history of prolonged bleeding episodes, menorrhagia, or epistaxis. Since infectious, auto-immune or metabolic diseases were excluded, a drug effect was ...
5
The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy
... 17Beta-estradiol, estrogen; EC: Endothelial cells; ECM: Extracellular matrix; eNOS: Nitric oxide synthase 3; EPC: Endothelial progenitor cells; ER: Estrogen receptors; ERKO: Estrogen receptor α ...
16
ERβ and ApoE isoforms interact to regulate BDNF–5-HT2A signaling and synaptic function in the female brain
... between estrogen signaling and ApoE isoforms in the regulation of neural activities in the central nervous system [48, ...that estrogen therapy (ET) was associated with lesser cogni- tive decline in ...
10
Nutrigenomic effects of edible bird’s nest on insulin signaling in ovariectomized rats
... and estrogen treatments in comparison with the OVX ...of estrogen-regulated insulin action in the rats (Figure 2). The estrogen group, on the other hand, showed significantly lower insulin levels ...
11
The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women
... that estrogen has met- abolic effects that are dependent on the route of administra- ...dermal estrogen administration increases GH and decreases IGF-I levels (1, ...oral estrogen therapy ...
7
Current treatment options for postmenopausal vaginal atrophy
... of estrogen deficiency can be carried out with hormonal preparations with systemic and local action, as well as with preparations of plant ...pharmacological estrogen preparations sufficiently and quickly ...
9
Management of osteoporosis and menopausal symptoms: focus on bazedoxifene/conjugated estrogen combination
... of estrogen production in women during menopause results in a state of estrogen deficiency which has been associated with multiple problems, including vasomotor symptoms, symptoms of vulvovaginal atrophy, ...
11
Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case control study
... oral estrogen or local estrogen ...oral estrogen is noteworthy, and tentatively important with regard to the biolog- ical mechanisms of breast ...hormone therapy are differen- tially ...
13
Hormone therapy and ovarian cancer: incidence and survival.
... cohort study, Lacey et al. detected a significantly increased risk of ovarian cancer in women who had used estrogen therapy for 10-19 years (HR=1.8, 95% CI: 1.1-3.0) or more than 20 years (HR=3.2, 95% CI: ...
23
Androgens and the breast
... against estrogen-induced mammary ...to estrogen therapy in ovariectomized rhesus monkeys significantly inhibits HT-induced mammary epithelial proliferation [3] (Figure ...epithelial estrogen ...
9
“Role of Aromatase and Anastrozole in Cancer Treatment” by Salam A. Mohammed, Firas Hassan, Anil K. Philip, Mays Abd-Allateef, Emad Yousif, Sultanate of Oman.
... as estrogen suppression therapy medical aid which regularly used as an adjuvant medical aid to cut back the chance of cancer back when surgery or cancer that has ...hormone therapy; it interferes ...
6
Estrogen monotherapy and combined estrogen progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterol fed rabbits
... Cardiovascular disease is currently the leading cause of death among women in the United States. To investigate the effect of postmenopausal hormone therapy on atherogenesis, we studied 75 cholesterol-fed female ...
7
Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis
... Estrogen dose analyses, adjusted for progestin use, were restricted to cur- rent users of CEE and EE. The daily, modal dose of CEE and EE was 0.625 mg. The low dose mean was 0.3 mg for CEE and EE; high dose mean ...
7
Medicinal Plants for the Treatment of Postmenopausal Osteoporosis
... Ovarian estrogen generation is the significant reason for bone loss which results in higher bone turn over between bone development and bone resorption(Ji & Yu, ...anabolic therapy to treat osteoporosis ...
16
microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy
... endocrine therapy-resistant breast cancer cell lines have revealed a miR-222- CDKN1B /p27 Kip1 expression network that is conserved in both tamoxi- fen-resistant and fulvestrant-resistant MCF-7 cells ...
19